SAN DIEGO—Ma Songjiang, President of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $1.1 billion market cap biotech company, recently sold shares of the company's common stock totaling $48,399, according to a recent SEC filing. According to InvestingPro analysis, the stock has shown significant momentum with an 11.6% gain over the past week, despite trading below its 52-week high of $30.39. The transactions, executed on December 23 and 24, were conducted under a Rule 10b5-1 trading plan.
In the first transaction on December 23, Ma sold 1,704 shares at a weighted average price of $12.24, with the shares being sold at prices ranging from $11.40 to $12.39. An additional 296 shares were sold the same day at a weighted average price of $12.44, within a price range of $12.41 to $12.48.
On December 24, Ma sold another 2,000 shares at a weighted average price of $11.93, with the sale prices ranging from $11.76 to $12.09. These transactions were made indirectly by Ma's spouse, leaving a total of 2,930,467 shares owned by Ma following these sales. InvestingPro subscribers can access additional insights, including 8 more ProTips and detailed financial metrics that help evaluate insider transactions in context.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.